Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
On May 16, 2017, Amyris, Inc. (the
Company) will be hosting its
1st Annual Biotech Summit and Investor Day (the
Investor Day), to be attended by
investors, partners and other parties. During the Investor Day,
representatives of the Company will present the presentation
filed as Exhibit 99.1 to this Current Report on Form 8-K (the
Investor Presentation). The Investor
Presentation will also be posted on the Investor Relations
section of the Company’s website, investors.amyris.com.
By filing this Current Report on Form 8-K and furnishing the
information contained herein, the Company makes no admission as
to the materiality of any information in this Current Report on
Form 8-K that is required to be disclosed solely by reason of
Regulation FD.
The information contained in the Investor Presentation is summary
information that is intended to be considered in the context of
the Companys filings with the Securities and Exchange Commission
(SEC) and other public announcements
that the Company may make, by press release or otherwise, from
time to time. The Company undertakes no duty or obligation to
publicly update or revise the information contained in this
Current Report on Form 8-K, although it may do so from time to
time as its management believes is warranted or as required by
applicable law. Any such updating may be made through the filing
of other reports or documents with the SEC, through press
releases or through other public disclosure.
The information in this Current Report on Form 8-K, including
Exhibit 99.1 attached hereto, is furnished to the rules and
regulations of the SEC and shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934 (the
Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits
The following exhibit is furnished herewith:
| Exhibit Number | Description |
| 99.1 | Investor Presentation |
About Amyris, Inc. (NASDAQ:AMRS)
Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product. Amyris, Inc. (NASDAQ:AMRS) Recent Trading Information
Amyris, Inc. (NASDAQ:AMRS) closed its last trading session down -0.025 at 0.295 with 8,047,629 shares trading hands.
